If you live with polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF), you may have heard your doctor mention your “mutation” or “allele burden.” A new review takes a close look at MRD monitoring in MPN, and I want to walk you through it in plain language. The review, by Gary Markey and Stephen […]
Interferon for Myelofibrosis: 2025 Study Challenges “Watch and Wait”
by David Wallace For years, the medical community has told us the same thing when we’re diagnosed with early-stage myeloproliferative neoplasms: “Let’s watch and wait.” The thinking was straightforward: why expose someone to treatment side effects when they’re not yet symptomatic? But a study published this December in the journal Cancers is challenging that entire […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
Ojjaara, FDA Approved for Treatment of Myelofibrosis with Anemia
September 15, 2023 Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease, and over 30% will discontinue […]
